• Zacks Investment Research Upgrades Capricor Therapeutics (CAPR) to Hold

    Capricor Therapeutics (NASDAQ:CAPR) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued …

    Read More
  • 0 0